An official website of the United States government
EGRP Cancer Epidemiology News
June 2024
- Dr. Erin Siegel Named Associate Director of NCI’s Epidemiology and Genomics Research Program
- Funding Opportunities
- Grants Policy Announcements
- Requests for Information or Collaboration
- Research Resources
- Job and Training Opportunities
- News and Blog Posts
Dr. Erin Siegel Named Associate Director of NCI’s Epidemiology and Genomics Research Program
Dr. Erin Siegel has been named Associate Director of the Epidemiology and Genomics Research Program (EGRP) for the National Cancer Institute's (NCI) Division of Cancer Control and Population Sciences (DCCPS). EGRP is the largest funder of cancer epidemiologic research worldwide; its focus is to support research in human populations to understand determinants of cancer occurrence and outcomes.
Prior to joining NCI in June 2024, Dr. Siegel was a Senior Member in the Departments of Cancer Epidemiology and Gastrointestinal Oncology at the Moffitt Cancer Center and Research Institute. She was also an Associate Professor in the Department of Oncologic Sciences in the University of South Florida’s College of Medicine. Dr. Siegel had an administrative leadership position as the inaugural Scientific Director of Moffitt’s Non-Therapeutic Research Office, a unique office dedicated to supporting the conduct of observational and cancer epidemiology studies.
Dr. Siegel has a wealth of experience building and leveraging patient cohorts and biorepositories to advance high-impact team science. She was a (Multiple) Principal Investigator of the ColoCare study — a large, multi-institutional, cohort study investigating outcomes among colorectal cancer (CRC) patients — and established the Moffitt ColoCare Site in 2009. She was a co-Investigator on several NIH research project grants (R01) that leveraged the infrastructure of the cohort to identify prognostic and predictive proteomic and metabolomic biomarkers of CRC recurrence, identify metabolomic and genomic predictors of cancer-related fatigue, and examine the association of body composition on CRC outcomes.
In addition, Dr. Siegel was instrumental in leading and providing strategic direction of Moffitt’s institutional biobanking protocol — the Total Cancer Care Protocol (TCC) — for over 10 years and served as PI since 2021. She was an active collaborator, leveraging TCC resources for research spanning multiple cancers, including CRC, multiple myeloma, and lung, kidney, and head and neck cancers. She has used multi-omics approaches to identify pan-cancer circulating biomarkers, including emerging biomarkers within exosomes, and has conducted molecular and clinical epidemiological studies focused on HPV-associated cervical, anal, and head and neck cancers.
Dr. Siegel’s recent scientific interests include cancer epidemiology and cancer survivorship research spanning lifestyle/behavioral factors, racial/ethnic disparities, and translational studies aimed at discovering and validating novel molecular, blood-based biomarkers related to the risk of adverse CRC outcomes.
Dr. Siegel has also been involved with and provided leadership to the Oncology Research Information Exchange Network (ORIEN) since 2014, most recently as its Steering Committee Chair. ORIEN is a national research network of 18 cancer centers in the United States that are focused on accelerating cancer research and advancing care through collaboration and partnerships.
Dr. Siegel earned both her PhD and MPH degrees in epidemiology from the Arizona College of Public Health, University of Arizona, in Tucson.
Funding Opportunities
- PAR-24-207, Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01, Clinical Trials Optional)
- RFA-CA-24-027, Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers (R01, Clinical Trial Optional)
- RFA-DA-25-026 , HEAL Initiative: JCOIN Phase II Community Engaged Research Resource Center (U24, Clinical Trial Optional)
- RFA-NR-24-006, Understanding the Intersection of Social Inequities to Optimize Health and Reduce Health Disparities: The Axes Initiative (R01, Clinical Trial Optional)
- NOT-CA-24-056, Notice of Special Interest (NOSI): Mechanisms Driving Obesity and Prostate Cancer Risk
- NOT-CA-24-060, NOSI: Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception Research
- NOT-OD-24-119, NOSI: Research Opportunities Centering the Health of Women Across the HIV Research Continuum
- NOT-MD-24-018, Notice of Intent to Publish a Funding Opportunity Announcement for Environmental Health Disparities Centers (P50)
Grants Policy Announcements
- NOT-CA-24-063, Preapplication Webinar: Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers
- NOT-OD-24-129
, Updates to NIH Institutional Training Grant Applications for Due Dates on or After January 25, 2025 - NOT-OD-24-123, Reporting Data Management and Sharing (DMS) Plan Activities in the Research Performance Progress Report (RPPR)
Requests for Information or Collaboration
- Survey on Engagement with NCI Division of Cancer Control and Population Sciences (responses due July 12, 2024)
- NOT-HL-24-014, Critical Challenges and Opportunities for Lymphatic Scientific, Clinical, and Disease Communities (responses due June 28, 2024)
- NOT-PM-24-003, Future Data Linkages within the Center for Linkage and Acquisition of Data for the All of Us Research Program (responses due June 28, 2024)
- NOT-CA-24-065, Seeking Input on Existing Study Populations with Multi-Cancer Detection (MCD) Test Results and Available Samples for Germline Testing (responses due July 15, 2024)
- NOT-CA-24-067, Seeking Input on Existing Study Populations with Germline Results and Samples Available for Multi-Cancer Detection (MCD) Assay Testing (responses due July 15, 2024)
- Federal Evidence Agenda on Disability Equity (responses due July 15, 2024)
- How can NIH strengthen stewardship through the development of robust measures for assessing the impact of its investments? (responses due July 22, 2024)
- NOT-RM-24-010, NIH Common Fund Is Soliciting Ideas for NIH-wide Challenges and Opportunities (responses due August 10, 2024)
- Strategies for Maximizing Public Engagement in NIH Supported Clinical Research (responses due August 14, 2024)
Research Resources
Job and Training Opportunities
- NCI Welcomes Letters of Interest for Chief of the Health Behaviors Research Branch
- NCI Postdoctoral Cancer Prevention Fellowship (applications due August 1, 2024)
News and Blog Posts
- Gene Variants and Breast Cancer Risk in Black Women
- Childhood Cancer Survivors May Benefit from Plant-Rich Foods
- Survivors Of Childhood Cancer Had Greater Risk of Major Adverse Cardiovascular Events Vs. Matched Community Controls
- Marking a Milestone: The Modernized ClinicalTrials.gov Becomes the Singular Website Experience
Stay Connected
Subscribe for Updates
Subscribe
You can subscribe and unsubscribe at any time by entering your email address and selecting your preferences on the page that follows.
Need Help?
EGRP staff can answer questions on grant funding, policies, and research resources. If you do not know who to contact we will do our best to connect you with someone who can help you.
Email Us(240) 276-6730